Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

UK Agency says Illumina-Pacific Biosciences Deal Raises Concerns

A U.K. competition watchdog said on June 18 that Illumina’s planned $1.2 billion acquisition of Pacific Biosciences raises anti-competitive concerns, at a minimum delaying the deal.

Tease photo

Arcturus Nets $30M in Expanded Collaboration with Ultragenyx

Ultragenyx paid San Diego’s Arcturus Therapeutics $6 million in cash and is poised to invest $24 million in the company following an expanded research agreement.

MappBio Awarded $16.5 Million For Work on Ebola-Like Viruses

BIOTECH: Antibody Was Isolated in Lab

MappBio — a once-little known San Diego biotech that captured worldwide interest with experimental drugs for Ebola and other viruses — landed another big contract.

Tech Startups Tackle Mental Health Care

HEALTH CARE: Reimbursement Codes Open Door for Revenue

The mental health system is often called broken or fragmented. That’s created an opening for San Diego tech companies.

Illumina Prevails in Patent Lawsuit Against Ariosa Diagnostics

A U.K. court today ruled that Roche subsidiary Ariosa Diagnostics infringed on an Illumina prenatal testing patent, the latest in the legal saga between the two companies.

CV Sciences Inks Distribution Deal with Kroger

CV Sciences’ CBD oil will be sold in 945 Kroger-owned stores across 17 states, it was recently announced.

Synthorx, Equillium And Turning Point Discuss IPOs

Investors Said Going Public Would Bring Increase in Investments

For biotechs, what’s the path to an initial public offering like? The CEOs of San Diego companies that took the IPO plunge weighed in on this question and others during a recent Biocom panel.

Ionis Appoints Joan Herman to its Board

Joan Herman was recently named to the board of Carlsbad’s Ionis Pharmaceuticals.

Reverse Merger To Support Co.’s Cancer Candidates

Oncternal Retains CEO, Will Remain In San Diego

On the heels of auspicious clinical trial results, San Diego-based Oncternal Therapeutics completed a reverse merger with Tennessee’s GTx, it was announced June 10.

Promising Results Boost Share Price of La Jolla Pharma

No New Treatments for Targeted Condition in More Than a Decade

La Jolla Pharmaceutical’s stock recently jumped after its drug candidate for regulating iron overload showed promise in preliminary clinical trial results.

Vical to Merge With Colo.-Based Brickell Biotech

Co.to Operate as Brickell, Focus on Skin Conditions

After pulling the plug on a herpes vaccine program, San Diego-based Vical is set to merge with Colorado’s Brickell Biotech in an all-stock deal.

Tease photo

Life Sciences Employment Shows Strong Growth

Average Wage Is $115,000; Economic Impact Put at $39B

Employment in San Diego’s life sciences industry increased 12.5% from 2013 to 2018, states a new report.

Evofem Closes $80M in Financing for Contraceptive Gel

After securing $30 million in a private stock placement in April, Evofem on June 10 closed a second tranche of $50 million.

UC San Diego Health Opens Primary Care Facility in Encinitas

UC San Diego Health opened an Encinitas facility as part of a bid to expand beyond hospital walls.

San Diego Hospitals Challenged by Jump in ER Use

ER Visits Rose 18% from 2012 to 2017, posing financial and operational difficulties

In 2013, Scripps Mercy Hospital’s emergency department doubled in size after a multiphase revamp. Six years later, Scripps officials said demand caught up.

Tease photo

La Jolla Pharmaceutical Surges on Interim Clinical Trial Data

La Jolla Pharmaceutical’s drug candidate for regulating iron overload showed promise in interim clinical trial data, sending the company’s stock soaring.

PCI Pharma Services to Open Third San Diego Site

Philadelphia-based PCI Pharma Services will open a third San Diego site, the company recently announced.

Tocagen Confident in Clinical Trial for Cancer Drug

Pharma: Analyst Says Main Targets Must Be Hit

Tocagen recently reported that a clinical trial of its brain cancer drug candidate will continue after an interim analysis. Afterward,its stock fell sharply, but company analysts were still mostly optimistic that the San Diego drug maker will deliver.

Tease photo

Settleman to Head Pfizer’s Oncology R&D Out of La Jolla site

Jeff Settleman on June 5 was named Pfizer’s group head of oncology and research development.

Inhibrx Files for Nearly $75M IPO

La Jolla-based Inhibrx on June 3 filed for a $74.75 million initial public offering to advance three cancer drugs in clinical trials and other programs.

San Ysidro Health Moving Toward Acquiring Mountain Health

San Ysidro Health has taken steps to acquire Mountain Health, another nonprofit that provides health care services to low-income San Diegans.

Up to $35 Million Awarded to Consortium Led by La Jolla Institute Scientist

A global effort to combat viral threats like Ebola that’s headed by a San Diego professor has been awarded up to $35 million.

Scientist.com Deal with 5AM Ventures Creates Marketplace for Biotech Startups

Solana Beach-based Scientist.com built an online marketplace for startups linked to 5AM Ventures that allows the early-stage firms to put specialty biotech services out to bid.

Agriculture Biotech Cibus Cancels IPO

Cibus – which uses gene editing to increase crop yields – called off its initial public offering, according to recently filed paperwork.

Inhibrx Receives $40M Investment

La Jolla-based Inhibrx recently took in a $40 million investment from Viking Global Investors to advance a pipeline targeting cancer, infectious disease and orphan diseases.

Evofem at Critical Stretch with Potential New Birth Control

BIOTECH: Contraceptive Gel Is Part of CEO's Health Mission for Women

Evofem Biosciences wants to be the next big thing in birth control. After a long road, the San Diego biotech finds itself in a pivotal stretch.

Tease photo

Life Sciences Occupancy Growth Down 44% in Q1

PROPERTY: Tenant Demand Still Robust; Rents Increase

San Diego’s life sciences cluster produced only 77,600 square feet of occupancy growth in the first quarter of the year.

Ra Medical Sues Strata Skin Sciences

LEGAL: Ra’s Lawsuit Centers On IPO

Carlsbad’s Ra Medical Systems is alleging a rival interfered with its initial public offering.

Tease photo

MabVax Sells Assets to German Company

BIOTECH: BioNTech Plans to Establish a Local Research Facility

The recent acquisition of San Diego’s MabVax has been a long time coming. MabVax sold its cancer drug assets and its lab equipment to German company BioNTech, it was announced earlier this month.

Trovagene and Nektar Strike Cancer Research Collaboration

San Diego’s Trovagene will partner with Nektar Therapeutics to explore combining their two drug candidates to treat metastatic colon cancer.

Locana Pulls in $55M to Repurpose CRISPR for RNA Therapies

Locana, a San Diego biotech that repurposed the gene-editing system CRISPR, has raised a $55 million series A round.

Reneo Pharmaceuticals Raises $50M Series A Round

San Diego’s Reneo Pharmaceuticals raised a $50 million Series A round to tackle metabolism and energy disorders.

Office Bridges Gap Between Discovery, Therapeutics

HEALTH: Arm of Moores Cancer Center Holds Annual Symposium

A department at UC San Diego Health’s Moores Cancer Center is known for putting on a symposium to translate groundbreaking oncology discoveries into therapeutics.

Tease photo

Chinese Pharma Co. Expands Its CRO Role in San Diego

PHARMA: Acquisitions Part of CRO Consolidation Trend Locally, Nationwide

WuXi AppTec is making moves in San Diego. The Chinese pharmaceutical company earlier this month bought San Diego-based Pharmapace.

Deploying AI at Hospitals Is Delicate Operation

HEALTH: Hospitals Grapple With Use, Costs and Concerns

Rady Children’s Hospital holds a world record for fastest genomic diagnosis. Instrumental in the feat: artificial intelligence.

Tease photo

AmpliPhi Biosciences Merges With Marina Del Rey Company

M&A: Co. Will Operate as Armata Pharmaceuticals

Two companies, new name. San Diego-based AmpliPhi Biosciences and Marina del Rey’s C3J Therapeutics have merged, operating as Armata Pharmaceuticals, focused on antibiotic-resistant infections.

Ra Medical Sues Strata Skin Sciences

Carlsbad’s Ra Medical Systems on May 16 sued Strata Skin Sciences and its board chair. The lawsuit alleges a campaign of false and misleading statements to financial partners before, during and after Ra Medical’s initial public offering.

Halozyme Reports Revenue Of $56.9 Million for First Quarter

BIOTECH: Co. Gets Licensing Fee From Argenx

San Diego-based Halozyme reported higher revenue and net income in first quarter results, thanks to the company’s platform technology. Looking forward, the company is heading for an inflection point.

Tease photo

Boston Scientific Acquires Carlsbad’s Vertiflex for $465M Upfront

Carlsbad-based Vertiflex – maker of a device that reduces spine pressure – was acquired by Boston Scientific. The deal includes Boston Scientific paying $465 million upfront, with additional payments dependent on commercial milestones over the next three years.

Local Medtechs Report Substantial Increases in Revenue for Quarter

medicine: Costs To Scale Up Leave Some Cos. in the Red

The heavy-hitters of San Diego medtech — Dexcom, ResMed, Tandem Diabetes Care and NuVasive — saw revenue either rise or shoot up in recent quarterly results.

Tease photo

Poseida Therapeutics Gains Orphan Drug Designation

A drug candidate from Poseida Therapeutics aimed at relapsed multiple myeloma has picked up an orphan drug designation.

Illumina Sues BGI Claiming Patent Infringement

Genomics titan Illumina has filed a patent infringement lawsuit against a BGI Group subsidiary.

Takeda’s New Site to Help Promote Key Relationships

life science: Also On the Move, BioLegend Claims Entire Street

Two biotechs, Takeda Pharmaceutical Co. and BioLegend, recently opened new campuses in San Diego.

Tease photo

Giant AMN to Expand With $200M Acquisition

HEALTH CARE: Florida Firm Gives It Telehealth Capabilities

AMN Healthcare’s recently announced acquisition will expand its footprint in fast-growing markets, while positioning the nation’s largest health staffing firm for what could be the wave of the future.

Tease photo

Wuxi Apptec Buys San Diego's Pharmapace

Wuxi Apptec earlier this month bought San Diego-based Pharmapace, the latest in consolidation among niche players in the drug development market.

UC San Diego Researchers Get $4.7M for Crohn’s Disease Efforts

Researchers at UC San Diego were awarded $4.7 million in grants to identify therapeutics and improve surgery for Chrohn’s disease.

MabVax Therapeutics Sells Assets

San Diego-based MabVax Therapeutics sold its cancer drug assets and its lab equipment to BioNTech, it was announced May 8.

Halozyme’s Revenue Jumps in Q1

San Diego-based Halozyme reported $56.9 million in first quarter revenue, an 84 percent year-over-year increase.

Abide Therapeutics Acquired for $250 Million Upfront

In search of therapies for brain diseases, Lunbeck will pay $250 million upfront to buy San Diego-based Abide Therapeutics.

Acadia Pharmaceuticals Reports $85.3M Loss in Q1

In first quarter results, Acadia Pharmaceuticals recorded an $85.3 million operating loss due to the company spending more on clinical research and marketing.

Prev